Analysis of Impurities in Atorvastatin

Význam tématu

Atorvastatin is one of the most commonly used lipid-lowering drugs, and monitoring its purity is critical for ensuring patient safety and regulatory compliance. Trace impurities can affect efficacy, cause adverse reactions, or indicate issues in manufacturing. A robust analytical approach is essential for reliable quantification and identification of these impurities in pharmaceutical formulations.

Cíle a přehled studie

This application note demonstrates a rapid and sensitive LC-MS method for separating and detecting atorvastatin and two known impurities. The goals are to achieve baseline resolution, to obtain mass spectral data for structural confirmation, and to illustrate the method’s suitability for routine quality control in drug development and production settings.

Použitá metodika a instrumentace

The study employs a Shim-pack XR-ODS reversed-phase column (50 mm × 2.0 mm, 2.2 µm) on a Nexera XR UHPLC system coupled to an LCMS-2050 mass spectrometer. Key parameters include:

• Mobile phase A: 10 mmol/L ammonium acetate aqueous solution
• Mobile phase B: acetonitrile; gradient from 10 % to 100 % B over 20 min
• Flow rate: 0.3 mL/min; column temperature: 40 °C; injection volume: 1 µL
• Detection: PDA (190–800 nm) and ESI/APCI positive ionization, scan range m/z 100–1000

Hlavní výsledky a diskuse

The method achieved clear separation of atorvastatin and two related impurities with retention times distinct enough for quantitation. Mass spectra obtained under both ESI and APCI conditions provided characteristic ion peaks for structural confirmation. The optimized nebulizing, drying, and heating gas flows, along with the interface voltage and desolvation temperature, ensured stable ionization and low background noise.

Přínosy a praktické využití metody

This LC-MS approach offers several benefits:

• High sensitivity for trace impurity detection
• Short analysis time suitable for high throughput
• Comprehensive structural information via MS scanning
• Compatibility with regulatory guidelines for pharmaceutical QC

Budoucí trendy a možnosti využití

Advances in column technology and ionization sources may further reduce run times and enhance detection limits. Coupling with high-resolution mass spectrometers or ion mobility spectrometry could improve the identification of unknown degradation products. Automation and integration with data analytics will streamline routine impurity profiling.

Závěr

The described LC-MS method provides a reliable platform for atorvastatin impurity analysis, balancing speed, sensitivity, and structural confirmation. Its adoption in pharmaceutical laboratories supports rigorous quality control and regulatory compliance.

Reference

Shimadzu Corporation. Application News 01-00261. First Edition: September 2024.